Skip to main content
Fig. 1 | Trials

Fig. 1

From: Experiences of the Data Monitoring Committee for the RECOVERY trial, a large-scale adaptive platform randomised trial of treatments for patients hospitalised with COVID-19

Fig. 1

Daily recruitment into the RECOVERY trial and periods of each main treatment assessment, March 2020 to February 2022. Scheduled (*) and emergency (†) DMC meetings. In addition to the main assessments shown, dimethyl fumarate vs usual care was assessed in 713 adults between March and November 2021, while additional assessments in children with paediatric multisystem inflammatory syndrome temporally associated with COVID-19 (PIMS-TS) have involved intravenous immunoglobulin vs high-dose methylprednisolone vs usual care (August 2020 to July 2021, 141 children) and anakinra vs tocilizumab vs usual care (May 2020 to January 2022, 75 children)

Back to article page

Trials

ISSN: 1745-6215